Page 83 - CIBERDEM2016-ENG

Most relevant scientific articles
• Zarei M., Barroso E., Leiva R., Barniol-Xicota M., Pujol E., Escolano C. et al. Heme-regulated eIF2α kinase modulates hepatic FgF21 and is activated by PPARβ/δ deficiency. Diabetes. 2016;65(10):3185- 3199.
• Tan N.S., Vazquez-Carrera M., Montagner A., Sng M.K., Guillou H., Wahli W. Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ. Progress in Lipid Research. 2016;64:98-122.
• Vazquez-Carrera M.. Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease. Trends in Endocrinology and Metabolism. 2016.
Highlights
During 2016 we have discovered that HRI (Heme-regulated eIF2alpha kinase) activators might be useful for the prevention and treatment of type 2 diabetes mellitus and additional metabolic diseases due to its ability to increase hepatic levels of FGF21 (Fibroblast growth factor 21). This finding allowed us to file the patent “HRI activators useful for the treatment of metabolic diseases”. Likewise, we have obtain research funds from the Fundación Bosch i gimpera of the University of Barcelona to perform a proof of concept with new HRI activators to prove their efficacy in an animal model of type 2 diabetes mellitus.
DEM
research groups 83